Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression
Open Access
- 1 January 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (1) , 143-156
Abstract
The complement cascade is a part of the innate immune system that acts primarily to remove pathogens and injured cells. However, complement activation is also peculiarly associated with tumor progression. Here we report mechanistic insights into this association in multiple immunocompetent orthotopic models of lung cancer. After tumor engraftment, we observed systemic activation of the complement cascade as reflected by elevated levels of the key regulator C3a. Notably, growth of primary tumors and metastases was both strongly inhibited in C3-deficient mice (C3−/− mice), with tumors undetectable in many subjects. Growth inhibition was associated with increased numbers of IFNγ+/TNFα+/IL10+ CD4+ and CD8+ T cells. Immunodepletion of CD4+ but not CD8+ T cells in tumor-bearing subjects reversed the inhibitory effects of C3 deletion. Similarly, antagonists of the C3a or C5a receptors inhibited tumor growth. Investigations using multiple tumor cell lines in the orthotopic model suggested the involvement of a C3/C3 receptor autocrine signaling loop in regulating tumor growth. Overall, our findings offer functional evidence that complement activation serves as a critical immunomodulator in lung cancer progression, acting to drive immune escape via a C3/C5–dependent pathway. Significance: This provocative study suggests that inhibiting complement activation may heighten immunotherapeutic responses in lung cancer, offering findings with immediate implications, given the existing clinical availability of complement antagonists. Cancer Res; 78(1); 143–56. ©2017 AACR.Keywords
All Related Versions
Funding Information
- NIH (R01 CA162226, R01 CA108610)
- NIH (R01 AI068730)
- Colorado Lung SPORE (P50 CA058187)
- United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service (IK2BX001282)
- NIH (P30CA046934)
- National Cancer Institute (P30 CA046934)
- NIH/NCATS (UL1 TR001082)
This publication has 33 references indexed in Scilit:
- Detection of complement activation using monoclonal antibodies against C3dJournal of Clinical Investigation, 2013
- T-helper-1-cell cytokines drive cancer into senescenceNature, 2013
- Activation of PPARγ in Myeloid Cells Promotes Lung Cancer Progression and MetastasisPLOS ONE, 2011
- PMX-53 as a Dual CD88 Antagonist and an Agonist for Mas-Related Gene 2 (MrgX2) in Human Mast CellsMolecular Pharmacology, 2011
- Cancer and the Complement CascadeMolecular Cancer Research, 2010
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Defective engraftment of C3aR−/− hematopoietic stem progenitor cells shows a novel role of the C3a–C3aR axis in bone marrow homingLeukemia, 2009
- TopHat: discovering splice junctions with RNA-SeqBioinformatics, 2009
- Depletion of Cytosolic Phospholipase A2 in Bone Marrow–Derived Macrophages Protects against Lung Cancer Progression and MetastasisCancer Research, 2009
- Modulation of the antitumor immune response by complementNature Immunology, 2008